Heureons Injection 150 IU/mL (Sodium Heparin)
Heparin Sodium
Injections · Prescription medication
Huons Co., Ltd.
MFDS item code 202004281 · Approved 2020.06.08 · Insurance code 670608601
Prevention of blood coagulation during use of an extracorporeal circulation device for hemodialysis
This medication is used to prevent blood coagulation during the use of an extracorporeal circulation device in blood dialysis. This allows blood to circulate smoothly during dialysis, increasing efficiency and ensuring safe treatment. By preventing blood coagulation, it helps reduce blockages in the device and keeps the dialysis time smooth. Therefore, it is effective in preventing blood coagulation in the extracorporeal circulation device during blood dialysis.
This drug is generally administered according to the following dosing regimen; however, the dose should be determined according to the case (e.g., symptoms), site of application, and purpose. Usually, adjust the dose according to age and symptoms so that, after administration of this drug, the whole-blood clotting time (Lee-White method) or whole-blood activated partial thromboplastin time (WBAPTT) is 2~3 times the normal value. Use during extracorporeal circulation (hemodialysis) For artificial kidney treatment, the appropriate dose for each patient is calculated before dialysis based on the results of an individual heparin sensitivity test. With systemic heparinization, 1,000~5,000 units are usually administered before the start of dialysis, followed after dialysis begins by continuous administration of 500~1,500 units per hour or intermittent additional doses of 500~1,500 units every hour. With regional heparinization, infuse 1,500~2,500 units per hour continuously and neutralize with protamine sulfate during extracorporeal circulation.
This medication is very potent and should only be used under the strict supervision of a physician. Extra caution should be exercised when used in patients with diseases that pose a high risk of bleeding, as various bleeding can occur in patients who have received this medication. It should not be administered to patients who are allergic to this medication, have inappropriate blood coagulation test results, are bleeding, or have severe liver or kidney disease. Additionally, patients who have had recent central nervous system or eye surgeries, those who have received spinal or epidural anesthesia, and those with a history of severe thrombocytopenia due to this medication should also be excluded from receiving it. Patients with consumptive coagulopathy, those with catheters inserted, pregnant women in late pregnancy, patients with impaired liver or kidney function, children, and the elderly should use this medication with caution and frequently check their blood coagulation status. This medication can cause a variety of side effects such as bleeding, thrombocytopenia, liver dysfunction, allergic reactions, skin abnormalities, etc., so if any unusual symptoms occur during administration, the physician should be notified immediately. Blood coagulation test results should be frequently monitored, and if there are signs of bleeding, the administration should be stopped or adjusted; stopping it suddenly may lead to a risk of thrombosis, so the dosage should be decreased gradually. If the anticoagulant effect of this medication needs to be rapidly reversed, protamine sulfate, an antidote, should be used. If there is a rapid decrease in platelet count, administration should be stopped immediately, and further tests should be conducted, as immunological thrombocytopenia caused by this medication may still occur after stopping administration. This medication can interact with various drugs, so if you are taking other medications, you must inform your doctor or pharmacist. Women who are pregnant or may become pregnant should exercise special caution during administration due to the risk of bleeding in the uterus and placenta while breastfeeding; however, this medication is safe as it does not pass into breast milk. In case of overdose, the risk of bleeding becomes very high, so one must go to the hospital immediately to receive an antidote, as side effects may occur during this process. When using this medication, thorough cleanliness of the injection site is required for infection prevention, and intramuscular injections should be avoided due to the risk of bleeding. Opened medications should be used immediately, and any remaining medication should be discarded; mixed injections with other medications should be avoided.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent air from entering, and it is important to maintain a storage temperature between 1 degree and 30 degrees Celsius at room temperature. Storing it this way will help maintain the medication's effectiveness for a long time.
A transparent solution that is colorless to light yellow, in a plastic container for injection.
20 milliliters/ampoule[* 50]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Heparin Sodium
Injections · Prescription medication
Huons Co., Ltd.
Heparin Sodium
Injections · Prescription medication
JW Pharmaceutical Corporation
Heparin Sodium
Prescription medication
Hallym Pharmaceutical Co., Ltd.
Heparin Sodium
Injections · Prescription medication
JW Pharmaceutical Co., Ltd.
Heparin Sodium
Prescription medication
Huons Co., Ltd.
Heparin Sodium
Prescription medication
Huons Co., Ltd.
Heparin Sodium
Injections · Prescription medication
Green Cross Corporation
Heparin Sodium
Prescription medication
Hyun's Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.